Phase 2 Clinical Trial of Tanespimycin in Patients With Advanced Malignancies After Failure of Previous Anti-cancer Therapy Regimens Who Have Participated on a Prior Protocol Investigating Tanespimycin

Inclusion Criteria:

- Age >= 18 years

- Participated in and completed a previous Tanespimycin protocol without evidence of
unacceptable toxicity and is deemed by the Investigator to be deriving benefit from
the Tanespimycin drug as defined in the previous protocol

- All patients must rollover to this continuation protocol within 30 days of the last
dose of Tanespimycin in the previous protocol, unless previously approved by the
Medical Monitor

- All Adverse Events from the prior protocol, must have resolved to NCI CTCAE (v. 3.0)
Grade <= 2

- The following laboratory results, within 10 days of Tanespimycin administration:

- Hemoglobin >= 8 g/dL

- Absolute neutrophils count >= 1.0x 10*9* /L

- Platelet count >= 50 x 10*9* /L

- Serum bilirubin <= 2 x ULN

- AST <= 2.5 ULN

- Serum creatinine <= 2 x ULN

- ECOG performance status of 0, 1 or 2

- Signed informed consent

Exclusion Criteria:

- Pre-existing neuropathy of CTCAE Grade >= 3 due to any cause

- Documented hypersensitivity reaction of CTCAE Grade >= 3 to prior therapy containing
Cremophor (for those patients receiving Tanespimycin Injection)

- Pregnant or breast-feeding women

- Administration of chemotherapy, biological, immunotherapy or investigational agent
(therapeutic or diagnostic), excluding Tanespimycin within 21 days prior to receipt
of study medication

- Any medical conditions that, in the Investigator's opinion, would impose excessive
risk to the patient